Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hereditary cerebral hemorrhage with amyloidosis (HCHWA), Italian type is a form of HCHWA characterized by an age of onset of 50 years of age, dementia and lobar intracerebral hemorrhage.
Biomarker and diagnostic research for ABeta amyloidosis, Italian type has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for ABeta amyloidosis, Italian type.
117 publications have been identified in PubMed for ABeta amyloidosis, Italian type. Research spans Review / Meta-Analysis (71%), Case Report / Case Series (8%), and Epidemiology / Natural History (8%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 83 | 71% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:58 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about ABeta amyloidosis, Italian type
Patient case studies
9 |
8% |
Disease patterns and progression | 9 | 8% |
Other research | 7 | 6% |
Laboratory research | 4 | 3% |
Testing and diagnosis research | 3 | 3% |
Clinical study results | 2 | 2% |
Greco F (2026). [PMID: 41777219](https://pubmed.ncbi.nlm.nih.gov/41777219/). *Anal Chem*. [Review / Meta-Analysis]
Li L (2026). [PMID: 41749115](https://pubmed.ncbi.nlm.nih.gov/41749115/). *BMC Nephrol*. [Review / Meta-Analysis]
Gomes CM (2026). [PMID: 41886557](https://pubmed.ncbi.nlm.nih.gov/41886557/). *Science*. [Review / Meta-Analysis]
Lewis E (2025). [PMID: 40862787](https://pubmed.ncbi.nlm.nih.gov/40862787/). *Curr Oncol*. [Review / Meta-Analysis]
Triposkiadis F (2025). [PMID: 39954876](https://pubmed.ncbi.nlm.nih.gov/39954876/). *Curr Probl Cardiol*. [Review / Meta-Analysis]
Kashchavtseva NA (2025). [PMID: 40327620](https://pubmed.ncbi.nlm.nih.gov/40327620/). *Ter Arkh*. [Case Report / Case Series]
Sekijima Y (2025). [PMID: 39627935](https://pubmed.ncbi.nlm.nih.gov/39627935/). *Amyloid*. [Review / Meta-Analysis]
Ghazal M (2025). [PMID: 40602734](https://pubmed.ncbi.nlm.nih.gov/40602734/). *Curr Probl Cardiol*. [Review / Meta-Analysis]
Tang J (2025). [PMID: 41002209](https://pubmed.ncbi.nlm.nih.gov/41002209/). *Rhode Island medical journal (2013)*. [Review / Meta-Analysis]
Ioannou A (2025). [PMID: 40650957](https://pubmed.ncbi.nlm.nih.gov/40650957/). *Future Cardiol*. [Review / Meta-Analysis]
AI-curated news mentioning ABeta amyloidosis, Italian type
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.